circling the wagons

[anonymous]

Home office is recalling budget from brands, the bleed is real. This is the first step to try and hide from all of us the business is in trouble. Next will be an evaluation of how much headcount is needed to appease the investors in France. Expect an announcement just before July holiday.

 

[anonymous]

Wait, I thought we are all going to be saved by Dysport? We'll be at $250M in no time. Who needs new data? We have a killer campaign!
#inthistilltheend

 

[anonymous]

Remember when Paulson’s leadership team started to resign en masse in 2020 (before he ended up getting fired in May 2021)? In addition to many of them deciding they couldn’t stomach the pompous, preening, obnoxious queen any longer the smart ones saw the writing on the wall. The downward spiral has already started.

 

[anonymous]

• You can add Paris-based Ipsen to the list of discount buyers patrolling the penny stock pack for a cheap M&A deal. The French biotech, which has had plenty of its own problems to grapple with, has swooped in to buy Epizyme for $247 million in cash and a CVR tied to sales of the EZH2a inhibitor cancer drug Tazverik.
  

 

[anonymous]

• You can add Paris-based Ipsen to the list of discount buyers patrolling the penny stock pack for a cheap M&A deal. The French biotech, which has had plenty of its own problems to grapple with, has swooped in to buy Epizyme for $247 million in cash and a CVR tied to sales of the EZH2a inhibitor cancer drug Tazverik.

 

[anonymous]

Home office is recalling budget from brands, the bleed is real. This is the first step to try and hide from all of us the business is in trouble. Next will be an evaluation of how much headcount is needed to appease the investors in France. Expect an announcement just before July holiday.

is Karyopharm next?